trial

This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

NCTId NCT03230097
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 50 (actual)
Sponsored by Boehringer Ingelheim
Primary completion 2021-03-17
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
50 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2017-09-29
Primary completion
2021-03-17
Eligibility
ALL · 16 Years · 30 Years

Interventions & indications

Drugs
BI 409306

Sponsors

Boehringer IngelheimLead Sponsor

Sites

33 total
Culver City, United StatesSan Diego, United StatesNew Haven, United StatesJacksonville, United StatesOrange City, United StatesAugusta, United StatesBoston, United StatesAnn Arbor, United StatesAnn Arbor, United StatesGrand Rapids, United StatesFlowood, United StatesLas Vegas, United States

Linked catalysts

1
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Men — primary completion2021-03-17

Facts & assertions

4 sourced
Enrollment
50
Phase
PHASE2
Primary Completion Date
2021-03-17
Status
TERMINATED
relationships
The graph out of here
drug
BI 409306
drug
lead_sponsor
Boehringer Ingelheim
company
indication
Psychotic Disorders
indication
Psychotic Disorders
indication